Increased neuroendocrine cells in resected metastases compared to primary colorectal adenocarcinomas.
Neuroendocrine differentiation has been described in rectal adenocarcinomas receiving neoadjuvant therapy prior to radical surgery, but its clinical relevance is controversial and no data are currently available in colorectal carcinoma metastases as compared to primary tumors. The presence of chromogranin A positive tumor cells was investigated by means of immunohistochemistry on surgical specimens from 54 primary colorectal carcinomas and their corresponding metastases, resected at diagnosis or during tumor progression. In 47 patients, tumor metastases were resected 1 month to 12 years after chemotherapy and/or radiotherapy, while in the remaining seven patients no additional therapy after primary surgery was performed. In primary tumors, neuroendocrine differentiation was found in 12/54 cases (22.2%) as compared to 25/54 metastatic lesions (46.3%; p = 0.01). The presence of neuroendocrine phenotype was not correlated with any clinical pathological parameter nor with a different proliferation index. However, patients having neuroendocrine cells in the primary tumor had a significantly shorter survival from the time of metastatic spread than those having not (33.3 vs. 55.5 months; p = 0.04). In summary, our data show that colorectal carcinoma metastases contain a higher percentage of neuroendocrine differentiated cells as compared to their corresponding primaries, a finding possibly related to the influence of chemotherapy in neuroendocrine differentiation during colorectal carcinoma progression.
Volante
Marco
M
University of Turin at San Luigi Hospital, Orbassano, Torino, Italy. marco.volante@unito.it
Marci
Valerio
V
Andrejevic-Blant
Snezana
S
Tavaglione
Veronica
V
Sculli
Maria Carla
MC
Tampellini
Marco
M
Papotti
Mauro
M
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology* / Q000556:secondary*; D000328:Adult; D000368:Aged; D002454:Cell Differentiation; D053379:Chromogranin A / Q000096:biosynthesis; D015179:Colorectal Neoplasms / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000378:metabolism / Q000556:secondary; D008175:Lung Neoplasms / Q000378:metabolism / Q000556:secondary; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000473:pathology*; D009367:Neoplasm Staging; D055099:Neuroendocrine Cells / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000556:secondary
D053379:Chromogranin A
Mod Pathol. 1995 Aug;8(6):626-32
8532695
Am J Surg Pathol. 2002 Jul;26(7):863-72
12131153
Int J Cancer. 1993 Jul 9;54(5):765-71
8100808
J Pathol. 1998 Oct;186(2):151-6
9924430
Cancer. 1992 Jun 1;69(11):2641-6
1571893
Hum Pathol. 1992 Jul;23(7):736-41
1351863
Breast. 2004 Aug;13(4):329-33
15325669
Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11
11338071
Histopathology. 2005 Feb;46(2):195-201
15693892
Cancer. 2003 May 15;97(10):2487-97
12733148
Semin Diagn Pathol. 2010 Feb;27(1):69-76
20306832
Prostate. 2010 May 15;70(7):718-26
20087896
Nature. 1997 Apr 24;386(6627):852-5
9126746
Mod Pathol. 2008 Jun;21(6):700-7
18311112
Virchows Arch. 1995;426(6):587-92
7655739
J Cancer Res Clin Oncol. 2007 Oct;133(10):783-5
17551754
J Cancer Res Clin Oncol. 2009 Aug;135(8):1055-9
19152002
Int J Surg Pathol. 2010 Jun;18(3):201-6
19372085
J Clin Pathol. 1995 Aug;48(8):754-8
7560204
Oncol Rep. 2008 Dec;20(6):1369-74
19020716
Am J Surg Pathol. 2006 Aug;30(8):945-53
16861964